Fujian Haixi New Drug Creation Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Fuzhou, Fujian. The company went IPO on 2025-10-20. The Company’s main products include Anbili, Haihuitong, Ruiantuo and Saixifu. The Company’s products are mainly used in digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases, inflammatory diseases, oncology, ophthalmology, respiratory diseases and others. The firm mainly operates its businesses in the domestic market.
02637.HK stock price ended at $152.2 on 星期一, after dropping 2.19%
On the latest trading day Jan 19, 2026, the stock price of 02637.HK fell by 2.19%, dropping from $155.70 to $152.20. During the session, the stock saw a volatility of 3.89%, with prices oscillating between a daily low of $151.50 and a high of $157.40. On the latest trading day, the trading volume for 02637.HK decreased by 38.1K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 27.8K shares were traded, with a market value of approximately $11.9B.